开放合作的资产

ADC资产

抗体药物偶联物（ADCs）结合了抗体的高特异性和小分子药物的强效细胞毒性，实现对癌细胞的精准靶向递送，同时减少对正常组织的损伤。该靶向策略不仅提升了治疗效果，还降低了全身毒性，使ADCs成为治疗难以靶向癌症的有前景的选择。
  • 20+
    双抗ADC资产
  • 200+
    TAA抗体骨架
获取数据包 预定会议
相关资源

在此页面上

  • 为什么选择百奥赛图的双抗ADC资产？
  • 30+ BsADC Programs Available for Partnership
  • 10+ ADC Programs Available for Partnership
  • 全人TAA抗体库
  • 部分资产概览

网络研讨会

查看全部

    海报

    查看全部
      为什么选择百奥赛图的双抗ADC资产？

      双特异性抗体药物偶联物（bsADC）通过同时靶向两种肿瘤相关抗原，旨在降低非肿瘤组织毒性并提升抗肿瘤效果。为助力新型bsADC的研发，我们团队构建了规模化bsADC发现平台，具备以下核心优势：

      • 全人共轻链抗体：我们的RenLite小鼠能够产生遗传多样性的全人源共轻链抗体骨架，这些骨架可组装成Y型双特异性抗体，便于CMC工艺的开发。
      • 新型连接子/毒素系统：采用专有的连接子/毒素系统BLD1102，该系统由超亲水性且可裂解的连接子和新型高效拓扑异构酶I抑制剂药物BCPT02组成，具有强效且显著的旁观者杀伤作用。此外，该系统在食蟹猴体内展现出良好的安全性。
      30+ BsADC Programs Available for Partnership
      Target(s) Immunization
      • Discovery
      • Hits
        selection         Leads
        selection         Candidate
        selection
      		Preclinical IND Phase I Status
      PTK7 x EGFR (BCG017)
      		Preclinical
      HER3 x EPCAM (BCG044)
      		Preclinical
      B7-H4 x B7-H4 (BCG040)
      		Preclinical
      B7-H3 x MUC1 (BCG041)
      		Preclinical
      PTK7 x TROP2 (BCG033)
      		Preclinical
      FOLR1 x MUC1 (BCG023)
      		Preclinical
      DLL3 x B7-H3 (BCG025)
      		Preclinical
      DLL3 x SEZ6 (BCG030)
      		Preclinical
      TPBG x MUC1 (BCG016)
      		Candidate Selection
      TROP2 x NECTIN-4 (BCG039)
      		Candidate Selection
      CDH17 x MET
      		Candidate Selection
      B7-H4 x EPCAM
      		Candidate Selection
      B7-H4 x HER3
      		Candidate Selection
      MUC1 x B7-H4
      		Candidate Selection
      TROP2 x B7-H4
      		Candidate Selection
      FOLR1 x FOLR1
      		Candidate Selection
      FAP x GPC1 (BCG026)
      		Candidate Selection
      MUC1 x TROP2 (BCG045)
      		Candidate Selection
      MSLN x CDH3
      		Candidate Selection
      MET x CDH3
      		Leads Selection
      MET x EPCAM
      		Leads Selection
      MET x B7-H3
      		Leads Selection
      FAP x B7-H3
      		Leads Selection
      CDH6 x FOLR1
      		Leads Selection
      MUC16 x FOLR1
      		Leads Selection
      EGFR x ITGB6
      		Leads Selection
      CD142 x NECTIN-4
      		Leads Selection
      MUC16 x FOLR1
      		Leads Selection
      CDCP1 x B7-H3
      		Leads Selection
      CDH3 x EGFR
      		Leads Selection
      CLEC12A x CD33
      		Leads Selection
      10+ ADC Programs Available for Partnership
      Target(s) Immunization
      • Discovery
      • Hits
        selection         Leads
        selection         Candidate
        selection
      		Preclinical IND Phase I Status
      CDH3 (BCG014)
      		CMC
      ITGB6 (BCG018)
      		CMC
      ADAM9 (BCG029)
      		Candidate Selection
      TM4SF5 (BCG015)
      		Candidate Selection
      PALP (BCG037)
      		Candidate Selection
      FOLR1(nano) (BCG047)
      		Candidate Selection
      DLL3(nano)
      		Candidate Selection
      CLDN1
      		Candidate Selection
      MSLN
      		Candidate Selection
      HHLA2
      		Leads Selection
      CDCP1 (BCG046)
      		Leads Selection
      EPHA5
      		Leads Selection
      CLDN4
      		Leads Selection
      CLDN3
      		Hits Selection
      全人TAA抗体库
      TAA-targeting antibody backbones available for flexible plug & play
      ADAM15 ADAM28 ADAM9 AFP ALB AMHR2 AMIGO2
      APLNR AXL B7-H4 BCMA CAIX CCL2 CCR9
      CD10 CD105 CD133 CD142 CD155 CD1D CD200R
      CD22 CD226 CD228 CD27 CD28 CD30 CD30L
      CD56 CD7 CD70 CD71 CD73 CD74 CD86
      CD98 CDCP1 CDH1 CDH11 CDH17 CDH3 CDH6
      CEACAM1 CEACAM5 CEACAM6 CHI3L1 CLDN3 CLDN4 CLDN6
      CLEC12A CRTAM DDR1 DLK1 DLL3 DLL4 DR5
      EFEMP1 EGFR EPHA2 EPHA4 EPHB2 FCRL5 FN1
      FOLR1 GPA33 GPA34 GPC-1 GPC3 GPNMB GPRC5D
      GUCY2C HER2 HER3 HHLA2 HLA-G HPN IGFBP2
      IL1RAP IL3RA ITGA7 ITGB6 JAM-A KIT LIV-1
      LUNX LY6G6D MET MRC2 MSLN MUC1 MUC13
      MUC16 MUC18 Nectin-4 PDGFRa PD-L2 PRLR PSMA
      PTK7 ROR1 SEMA4B SEZ6 SSTR2 TIM1 TPBG
      TREM2 TROP2 TWEAKR TYRO3 and more
      部分资产概览

      百奥赛图与全球多家ADC企业达成了合作关系，包括IDEAYA、ABL Bio、Ona Therapeutics和ADC Therapeutics。联系我们，探索评估、许可或共同开发的机会！

      PTK7×EGFR 双特异性抗体偶联药物
      BCG017 亮点
      • PTK7 与 EGFR 在多种实体瘤中共表达
      • BCG017 表现出协同效应，并有效应对肿瘤异质性
      • 通过利用中等亲和力的 EGFR 结合臂，该方法在单独与 EGFR 作用时，表现出内化减少和效力降低，这可能减少正常组织中 EGFR 介导的毒性。
      • 优异的血浆稳定性（孵育 21 天后游离载荷低于 0.5%，低于 Enhertu）
      在多种 PDX 模型中具有优异的疗效
      PDX cancer type PTK7 H score EGFR H score bsADC vs bencchmark ADCs
      BP1395 breast 61 241 superior
      BP0595 breast 107 188 superior
      BP0847 CRC 29 215 superior
      BP1013 gastric 124 96 superior
      BP0634 gastric ultra low 84 comparable
      BP0554 NSLCL 6 265 superior
      BP0865 esophagus 73 269 comparable
      BP0203 pancreatic 27 266 comparable
      PTK7 与 EGFR 在多种癌细胞类型中共表达
      Co-expression of PTK7 x EGFR in multiple cancer cell types
      当两个靶点均表达时，结合力最强
      Strongest binding when both targets are expressed